News

argenx Schedules Call for 2024 Financial Results Review

argenx Schedules Call for 2024 Financial Results Review

Upcoming Financial Results Announcement

February 20, 2025 – argenx (Euronext & NASDAQ: ARGX) has announced a significant upcoming event. The global immunology company, dedicated to enhancing the lives of those facing severe autoimmune diseases, will host a conference call and audio webcast to discuss its financial performance and business insights.

Conference Call Details

The event is scheduled for Thursday, February 27, 2025, at 2:30 PM CET (8:30 AM ET). In this session, argenx will present its full-year financial results for 2024 and provide an update on its fourth-quarter operations.

How to Access the Webcast

Interested parties can access the live audio of the call via the Investors section of the argenx website. Following the event, a recording will be available for one year, ensuring that those unable to attend live can still catch up on the significant information shared.

Dial-In Numbers for Participants

Here are the dial-in numbers for various countries:

Belgium: 32 800 50 201
France: 33 800 943355
Netherlands: 31 20 795 1090
United Kingdom: 44 800 358 0970
United States: 1 800 715 9871
Japan: 81 3 4578 9081
Switzerland: 41 43 210 11 32

For participation, use the access code 3810049 and join the call 15 minutes early to ensure smooth entry.

About argenx

As a leader in immunotherapy, argenx focuses on addressing critical needs in the autoimmune disease landscape. Collaborating with leading academic institutions through its Immunology Innovation Program (IIP), the company transforms innovative technologies into effective antibody-based therapies.

Innovative Therapeutics

Among its key advancements, argenx developed the first globally approved neonatal Fc receptor (FcRn) blocker, used in multiple countries including the U.S., Japan, and EU regions. Their lead product, efgartigimod, is under evaluation for various serious autoimmune conditions and is part of a broader strategy involving several early-stage antibody candidates.

Ongoing Research and Development

The commitment to research and innovation remains central to argenx’s mission. With a strong focus on developing new therapies, the company aims to improve patient outcomes through advanced science and clinical trials.

Connect with argenx

For more detailed updates, visit www.argenx.com and connect through their social media platforms, including LinkedIn and Instagram.

Frequently Asked Questions

What is the purpose of the upcoming conference call?

The conference call is intended to discuss argenx's financial results for 2024 and provide updates on its business operations.

When is the conference call scheduled?

The call will take place on February 27, 2025, at 2:30 PM CET (8:30 AM ET).

How can I listen to the conference call?

Individuals can access the call through the Investors section of the argenx website.

What are some of argenx's key products?

One of the highlighted products is efgartigimod, the first approved neonatal Fc receptor blocker, undergoing evaluation for various autoimmune diseases.

How can I get in touch with argenx for inquiries?

For media inquiries, you can contact Ben Petok at bpetok@argenx.com. For investor questions, reach out to Alexandra Roy (US) at aroy@argenx.com or Lynn Elton (EU) at lelton@argenx.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Verdafero Gains Ground in Sustainable Hospitality

Updated Category News Views 0

Verdafero's Latest Milestone: A Broader Environmental Reach It’s a day like today that makes you pause and realize that businesses in the hospitality space aren’t just about fluff and fancy lobbies anymore. They've got a new wave of responsibilities, especially with the globe pretty much on fire, literally and figuratively. Verdafero, a name not new to function and...

Continue Reading
Beazer Homes Sale Scrutinized for Shareholder Impact

Updated Category News Views 3

Spotlight on Beazer Homes' Proposed Sale Here's a real head-scratcher for folks in the stock trenches: Beazer Homes USA, Inc. (NYSE: BZH) finds itself under the microscope with Halper Sadeh LLC stirring the pot. You can't make this up—just another day in the world of investor rights and looming litigation. Questions Arise Over Shareholder Gains Halper Sadeh LLC, that...

Continue Reading
Innventure Faces Major Lawsuit Amidst Market Turmoil

Updated Category News Views 0

The Plot Thickens with Innventure's DarkNX Project Buckle up, fellow market sling-riders; the Innventure tale is a rocky one for the books. Imagine this: You’ve plunked down your hard-earned cash on Innventure Inc. (NASDAQ: INV), lured by their glowing pronouncements about a supposed golden egg project, the Accelsius DarkNX data-center deal. A big talk about...

Continue Reading
Regeneron Faces Class Action Over Tumultuous Trial Results

Updated Category News Views 3

Regeneron's Meltdown: A Bitter Pill for Investors Let’s dive headlong into the mess Regeneron Pharmaceuticals (NASDAQ:REGN) finds itself in—a classic nightmare scenario for investors. News broke like an old valve bursting, and suddenly, the market's love for Regeneron ran ice-cold. Who's to blame this time? Well, you might want to point a finger at the failed Phase 3...

Continue Reading
Lyon Biennale 2026: Art, Dreams, and Lyon's Magic

Updated Category News Views 3

Unveiling the Art Spectacle in Lyon Alright, buckle up folks, because the 18th Lyon Biennale – Contemporary Art is about to take the stage in grand fashion. Starting on the 19th of September, this art fiesta is not just any exhibit; it's an eleven-venue citywide takeover that runs until the 13th of December, and it is poised to shake up the art scene like a good splash...

Continue Reading
Reliable Safety & Flow: A New Era in Infrastructure

Updated Category News Views 3

Seismic Merger: Reliable Sprinkler and ASC Join Forces When two companies with roots stretching back to the 1800s decide to merge, it's not just a business move—it's a bold statement. Reliable Automatic Sprinkler and ASC Engineered Solutions, with over 175 years of combined innovation, have officially become Reliable Safety & Flow Corporation. This ain't just a...

Continue Reading
Stoke Space Raises $1B; XTEND AI Hits NYSE

Updated Category News Views 0

A Billion-Dollar Boost for Stoke Space Ever catch wind of a company hauling in a cool billion and shrug it off? Me neither. Stoke Space Technologies just locked down $1 billion in Series E funding. This ain't some pocket change—the kind of dough you need when you're eyeing stars and plotting orbital voyages. They're gearing up for a 2027 mission with their Nova...

Continue Reading
Indiana Fire Safety: The Importance of Regular Inspections

Updated Category News Views 4

Everybody thinks of fire extinguishers as those red cans hanging quietly on walls, but there's more to them than meets the eye. In Central Indiana, these devices are a literal lifeline, and neglecting their upkeep is playing with fire—literally. What Makes Monthly Checks a Big Deal? Fire extinguishers aren't just there for decoration. They're critical safety gear. This...

Continue Reading
Papa John's Faces Investor Lawsuit: Class Action Looms

Updated Category News Views 1

Papa John's in Hot Water Again? Look, just when you think the pizza game is all dough and cheesy goodness, along comes a legal scuffle to toss our assumptions. Bronstein, Gewirtz & Grossman, LLC has slapped a class action lawsuit against Papa John's International, Inc. (NASDAQ: PZZA), claiming the company and some of its higher-ups haven't been playing fair with the...

Continue Reading
Sony Meets Hello Kitty: A Collector's Audio Dream

Updated Category News Views 5

Unlikely Duo in Consumer Electronics It's time to listen up, and I mean literally. Who would've thunk it? Sony teams up with Hello Kitty for a limited-edition headphone collection that could make both audiophiles and pop-culture fanatics turn their heads faster than a rollercoaster. Now, I may have seen my fair share of wacky collaborations in my day, but the camaraderie...

Continue Reading

Top 5 Most Recently Viewed Articles

Vista Energy Expands Market Presence with PEPASA Acquisition

Updated Category News Views 321

Vista Energy's Strategic Move in the Oil Sector Vista Energy, S.A.B. de C.V. (NYSE: VIST), has expanded its portfolio by acquiring Petronas E&P Argentina S.A. This strategic acquisition marks a significant step in Vista's ambition to enhance its operational scale in the energy-rich Vaca Muerta region. The deal, valued at approximately US$ 900 million plus equity, provides...

Continue Reading
Tesla's Ambitious Cybercab Reveal Falls Short of Expectations

Updated Category News Views 196

Tesla's Cybercab launch back in 2024 was supposed to be a game-changer, but boy did it turn into a mixed bag. CEO Elon Musk stood up there, hyping this self-driving taxi model with all the flair you'd expect—like it's some kind of magic wand for urban transport. But when the dust settled, investors were left scratching their heads. I mean, who walks away from a big...

Continue Reading
TransMedics Group Inc Faces Class Action Lawsuit for Investor Losses

Updated Category News Views 86

TransMedics Group Inc Faces Legal Challenges TransMedics Group, Inc. is currently embroiled in a class action lawsuit that has drawn significant attention from investors and the legal community alike. This leading medical technology company is accused of making misleading statements about its business practices, prompting concerns from those who have invested in its...

Continue Reading
DFDS November Passenger and Freight Volume Trends Explored

Updated Category News Views 68

Insight into DFDS' November Volume Performance In the ferry sector, November 2025 witnessed total freight volumes reaching 3.6 million lane meters. When compared to the same month in 2024, this represents a decrease of 1.8%. If we adjust for route changes, the decline stands at 3.8%. The year-to-date (YTD) growth rates reflect a slight drop of 0.4% and 1.8%, respectively....

Continue Reading
Gould Expands with Mississippi Factory Acquisition

Updated Category News Views 14

Gould Industries Expands South of the Border Coming from north of the line, Gould Industries is making its mark in Mississippi. This handshaking between Canada and the U.S. through the acquisition of a big-time facility in Summit could be a game-changer for the company. Trust an old trader like me: when companies start hopping borders, they're looking at scaling up real...

Continue Reading